A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

A new FDA-approved drug brings in a lot of hope for men with aggressive prostate cancer, as it may increase their chances of survival by 40 per cent. According to experts, the combination of two drugs ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.

Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...

Nigeria records over 18,000 new prostate cancer cases annually, accounting for the highest cancer burden among men in the country.

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...

Findings expand Telomir-1’s oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. In this ...

Prostate cancer is a serious health issue around the world. The Indian Journal of Urology states that it is the second most common cancer in men, making up about 14.2% of new cancer cases. Despite its ...

Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1’s consistent impact on cancer cell survival pathways. MIAMI, ...